Research Associate Professor, International Health
Kennedy School of Government, Harvard University, MPA
- Office: Crosstown Center, CT390
- Phone: 617-414-1273
- Email: firstname.lastname@example.org
Sydney Rosen, MPA, is Research Associate Professor at the Center for Global Health & Development at Boston University and the Co-Director of the Health Economics and Epidemiology Research Office (HE2RO) of the Wits Health Consortium at the University of the Witwatersrand in Johannesburg, South Africa. Her research addresses the economic consequences of the HIV/AIDS epidemic, including the impact of HIV/AIDS on households, private sector companies, and public sector agencies in sub-Saharan Africa; the benefits and costs of prevention and treatment interventions; and sectoral and societal responses to the epidemic. She is the principal investigator of USAID-, CDC-, NIH-, and foundation-supported evaluations of the outcomes, costs, benefits, and cost-effectiveness of care and treatment for HIV/AIDS in South Africa, Zambia, and Kenya. Her current research focuses on the costs and cost-effectiveness of different strategies for large-scale antiretroviral treatment provision. She is also the author of policy and review papers on the business response to AIDS, the rationing of antiretroviral therapy, and the retention of patients in AIDS treatment programs. Her research has been published in The Lancet, PloS Medicine, AIDS, JAIDS, the Bulletin of the World Health Organization, Tropical Medicine and International Health, and other international journals. In 2003 she won the Harvard Business Review’s McKinsey Award, given to the most influential Harvard Business Review article of the year, for her article titled “AIDS is Your Business.” Professor Rosen’s technical training is in policy analysis and applied economics. She holds a BA magna cum laude from Harvard University and an MPA from the Kennedy School of Government at Harvard.
- AIDS and the Private Sector in Africa
- Costs and Outcomes of HIV/AIDS Treatment and PMTCT in Zambia
- Costs and Outcomes of HIV/AIDS Treatment in Kenya
- Costs and Outcomes of HIV/AIDS Treatment in South Africa
- Economic and Quality of Life Outcomes for Patients on ART in Kenya
- Economic Outcomes of HIV/AIDS Treatment in South Africa
- Economics and Epidemiology of HIV/AIDS, Tuberculosis, and Non-Communicable Diseases in Africa and Asia
- Economics of Tuberculosis Prevention and Treatment in South Africa
- Epidemiologic Analyses and HIV Treatment Outcomes in South Africa
- Factors Influencing Enrollment in Treatment for HIV/AIDS in Zambia
- Impact of HIV/AIDS on Four Sectors in Zambia (Tourism, Agriculture, Health Care, and Judiciary)
- INROADS: Innovations Research on HIV/AIDS
- Labor Productivity and Antiretroviral Therapy in Kenya
- Loss to Follow-up for HIV Treatment in South Africa
- Loss to Initiation of HIV Care and Treatment in South Africa
- RapIT: Rapid Initiation of Antiretroviral Therapy to Promote Early HIV/AIDS Treatment in South Africa
Health Economics and Epidemiology Research Office (HE2RO); 2014 Jun.
Retention in care, resource utilization, and costs for adults receiving antiretroviral therapy in Zambia: a retrospective cohort study
BMC Public Health. 2014 Mar; 14(296).
Effect of antiretroviral therapy on patients’ economic well-being: five-year follow up in South Africa
AIDS. 2013 Sep;.
Uptake, Outcomes, and Costs of Antenatal, Well-Baby, and Prevention of Mother-to-Child Transmission of HIV Services under Routine Care Conditions in Zambia
PLOS ONE. 2013 Aug; 8(8).
Same-Day CD4 Testing to Improve Uptake of HIV Care and Treatment in South Africa: Point-of-Care Is Not Enough
AIDS Research and Treatment. 2013 Jun; 2013:1-7.
Retention in Care and Outpatient Costs for Children Receiving Antiretroviral Therapy in Zambia: A Retrospective Cohort Analysis
PLoS ONE. 2013 Jun; 8(6).
The South African Medical Journal. 2013 Feb; 103(2).
AIDS 2012. 2013 Jan; 14(27):243-250.
Antiretroviral Therapy, Labor Productivity, and Gender: A Longitudinal Cohort Study of Tea Pluckers in Kenya
AIDS 2012. 2013 Jan;.
Rates and Cost of Hospitalization Before and After Initiation of Antiretroviral Therapy in Urban and Rural Settings in South Africa
JAIDS. 2013 Jan; 62(3):322-328.
ART treatment costs and retention in care in Kenya: a cohort study in three rural outpatient clinics
Journal of the International AIDS Society. 2013 Jan; 16(18026).
Tropical Medicine and International Health. 2012 Dec;.
Defining retention and attrition in pre-antiretroviral HIV care: proposals based on experience in Africa
Tropical Medicine and International Health. 2012 Aug; 00(00):1-10.
HIV treatment produces economic returns through increased work and education, and warrants continued US support
Health Affairs. 2012 Jul; 31(7):1470-1477.
Scaling up Xpert MTB⁄RIF technology: the costs of laboratory vs. clinic-based roll-out in South Africa
Tropical Medicine and International Health. 2012 Jun; 00(00):1-10.
PLoS ONE. 2012 May; 7(5):1-11.
How to Estimate the Cost of Point-of-Care CD4 Testing in Program Settings: An Example Using the Alere PimaTM Analyzer in South Africa
PLoS ONE. 2012 Apr; 7(4):1-8.
Rapid, Point-of-Care CD4 Testing At Mobile and Fixed HIV Testing Sites: Does It Increase Linkage to HIV Care?
Health Economics and Epidemiology Research Office (HERO). 2011 Nov; 3:1-2.
The Net Cost of Incorporating Resistance Testing into HIV/AIDS Treatment in South Africa: A Markov Model with Primary Data
Journal of International AIDS Society. 2011 Jul; 14(24):1-6.
PLOS Medicine.. 2011 Jul; 8(7):1-16.
Treatment Outcomes and Cost-Effectiveness of Shifting Management of Stable ART Patients to Nurses in South Africa: An Observational Cohort
PLOS Medicine. 2011 Jul; 8(7):1-10.
The Incremental Cost Of Introducing Xpert® MTB/RIF into the South African National Tuberculosis Programme
Johannesburg, South Africa; Boston, MA: Health Economics and Epidemiology Research Office, Wits Health Consortium, University of the Witwatersrand (HE2RO); 2011 Jul.
PLoS Medicine. 2011 Jul; 8(7):1-16.
Lost Opportunities to Complete CD4+ Lymphocyte Testing Among Patients Who Tested Positive for HIV in South Africa
Bull World Health Organ. 2010 Sep; 88(9):675-80.
Total Cost and Potential Cost Savings of the National Antiretroviral Treatment (ART) Programme in South Africa 2010 to 2017. Abstract 16112
18th International AIDS Conference; 2010 Jul 18; Vienna.
Patient Retention in Antiretroviral Therapy Programs Up to Three Years on Treatment in Sub-Saharan Africa, 2007-2009: Systematic Review
Trop Med Int Health. 2010 Jul; 15 Suppl 1:1-15.
Early Loss to Follow Up After Enrolment in Pre-ART Care at a Large Public Clinic in Johannesburg, South Africa
Trop Med Int Health. 2010 Jul; 15 Suppl 1:43-7.
Trop Med Int Health. 2010 Jul; 15 Suppl 1:48-54.
Cost of Using a Patient Tracer to Reduce Loss to Follow-Up and Ascertain Patient Status in a Large Antiretroviral Therapy Program in Johannesburg, South Africa
Trop Med Int Health. 2010 Jul; 15 Suppl 1:98-104.
Improvements in Physical Wellbeing over the First Two Years on Antiretroviral Therapy in Western Kenya
AIDS Care. 2010 Apr; 22(2):137-45.
Survival in Care and CD4 Cell Count Gain on First-line ART Depend on Prior CD4 Cell Count and Time on Treatment: Evidence From a Large South African Cohort. Abstract Z-184
17th Conference on Retroviruses and Opportunistic Infections (CROI); 2010 Feb 1; San Francisco.
AIDS. 2010 Jan; 24(6):915-9.
Economic Outcomes of Patients Receiving Antiretroviral Therapy for HIV/AIDS in South Africa Are Sustained through Three Years on Treatment
PLoS ONE. 2010 Jan; 5(9):e12731.
Economic and Quality of Life Outcomes of Antiretroviral Therapy for HIV/AIDS in Developing Countries: a Systematic Literature Review
AIDS Care. 2009 Dec; 21(11):1343-56.
Do the Socioeconomic Impacts of Antiretroviral Therapy Vary by Gender? A Longitudinal Study of Kenyan Agricultural Worker Employment Outcomes
BMC Public Health. 2009 Jul; 9:240.
The changing HIV/AIDS landscape : selected papers for the World Bank's agenda for action in Africa, 2007-2011. Lule Elizabeth, Seifman Richard, David Antonio C., World Bank.. Washington DC: World Bank; 2009.
From the Ground Up: Developing Pathways and Partnerships. Richard G. Marlink and Sara J. Tietelman. published online: Elizabeth Glaser Pediatric AIDS Foundation; 2009.
Differences in Normal Activities, Job Performance and Symptom Prevalence between Patients Not Yet on Antiretroviral Therapy and Patients Initiating Therapy in South Africa
AIDS. 2008 Aug; 22 Suppl 1:S131-9.
Characteristics of Patients Accessing Care and Treatment for HIV/AIDS at Public and Nongovernmental Sites in South Africa
J Int Assoc Physicians AIDS Care (Chic Ill). 2008 Jul; 7(4):200-7.
The Outcomes and Outpatient Costs of Different Models of Antiretroviral Treatment Delivery in South Africa
Trop Med Int Health. 2008 Jul; 13(8):1005-15.
Cost and Cost-Effectiveness of Switching from Stavudine to Tenofovir in First-Line Antiretroviral Regimens in South Africa
J Acquir Immune Defic Syndr. 2008 Jun; 48(3):334-44.
Curr HIV/AIDS Rep. 2008 Mar; 4(4):192-200.
Early Effects of Antiretroviral Therapy on Work Performance: Preliminary Results from a Cohort Study of Kenyan Agricultural Workers
AIDS. 2008 Jan; 22(3):421-5.
From the Ground Up: A Guide to Comprehensive HIV/AIDS Care in Resource-Limited Settings. Marlink R, et al.. Santa Monica, CA: Elizabeth Glaser Pediatric AIDS Foundation; 2008.
PLoS Med. 2007 Oct; 4(10):e298.
S Afr Med J. 2007 Sep; 97(7):524-9.
AIDS. 2007 Aug; 21 Suppl 3:S41-51.
AIDS. 2007 Aug; 21 Suppl 3:S53-9.
S Afr Med J. 2007 Apr; 97(2):115-20.
Health, Economic Development and Household Poverty: From Understanding to Action. Bennet S., Gilson L., Mills A.. London, England: Taylor and Francis, Routledge; 2007.
S Afr Med J. 2006 Mar; 96(2):128-33.
HIV/AIDS and the Private Sector in Africa: Impact and Responses. Report prepared for the Commission on HIV/AIDS and Governance in Africa
Boston, MA: Center for International Health and Development; 2006 Feb.
Boston, MA: Center for International Health and Development, Boston University; 2006.
PLoS Med. 2005 Sep; 2(11):e303.
Lancet. 2005 Jun; 365(9475):1925-6.
Assessing the Potential for Insurance and Other Private Sector Financing Mechanisms to Increase Access to HIV/AIDS Services in Sub-Saharan Africa
Prepared for USAID. Washington, D.C.: USAID; 2005.
Lancet. 2005 Jan; 365(9456):354-6.
Opportunities to Expand HIV/AIDS Services to Employees of Small and Medium-Sized Companies in Wynberg, South Africa
Project report; 2005 Jan 1; 2005/01/01.
Cost Impact of HIV/AIDS Infections in the Professional Labor Force in the Zambian Health Care System
XVth International AIDS Conference; 2004 Jul 1; Bangkok, Thailand.
AIDS. 2004 Apr; 18(2):317-24.
S Afr Med J. 2004 Mar; 94(2):125-30.
Trop Med Int Health. 2004 Mar; 9(3):318-24.
Boston, MA: Center for International Health and Development; 2004.
Journal of Business in Developing Countries. 2004 Jan; 8(1):1-38.
Bull World Health Organ. 2003 May; 81(2):131-7.
Harv Bus Rev. 2003 Feb; 81(2):80-7, 125.
How Will the Reduction of Tariffs and Taxes on Insecticide- Treated Bednets Affect Household Purchases?
Bull World Health Organ. 2002 Dec; 80(11):892-9.
Soc Sci Med. 2002 Aug; 55(4):571-84.
Development Discussion Paper. Boston, MA: Harvard Institute for International Development; 2000.
World Development. 1999 Oct; 27(10):1803-1819.
Development Discussion Paper. Boston, MA: Harvard Institute for International Development; 1999.